Novavax, Inc.: Novavax Submits Request to Expand Conditional Marketing Authorization of COVID-19 Vaccine in the European Union to Adolescents (Ages 12-17)
If granted, Nuvaxovid COVID-19 Vaccine (recombinant, adjuvanted) would be the first protein-based option for adolescents aged 12-17 years in EuropeGAITHERSBURG, Md., March 31, 2022 /PRNewswire/